UPADACITINIB IMPROVES STEROID-FREE CLINICAL AND ENDOSCOPIC ENDPOINTS IN PATIENTS WITH CROHN'S DISEASE: DATA FROM THE CELEST STUDY

被引：0
|
作者：
Panaccione, Remo
Atreya, Raja
Ferrante, Marc
Dubinsky, Marla
Sands, Bruce E.
Abreu, Maria T.
Cataldi, Fabio
Enejosa, Jeffrey V.
Zhou, Qian
Huang, Bidan
Lacerda, Ana P.
Pangan, Aileen L.
机构：
来源：
GASTROENTEROLOGY | 2018年 / 154卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
Sa1758
引用
收藏
页码：S384 / S384
页数：1
相关论文
共 50 条
  • [21] Achievement of steroid-free remission in patients with moderately to severely active Crohn's Disease during treatment with risankizumab
    Schreiber, S. W.
    Cross, R.
    Panaccione, R.
    D'Haens, G.
    Bossuyt, P.
    Colombel, J. F.
    Louis, E.
    Dubinsky, M.
    Kligys, K.
    Neimark, E.
    Song, A.
    Zambrano, J.
    Cheng, E.
    Ferrante, M.
    JOURNAL OF CROHNS & COLITIS, 2022, 16 : I125 - I126
  • [22] Induction of endoscopic response, remission and ulcer-free endoscopy with upadacitinib is associated with improved clinical outcomes in patients with Crohn's disease
    Panes, J.
    Louis, E.
    Bossuyt, P.
    Joshi, N.
    Lee, W. J.
    Lacerda, A.
    Remple, V.
    Xuan, S.
    Loftus, E. V., Jr.
    JOURNAL OF CROHNS & COLITIS, 2023, 17 : 919 - 920
  • [23] ACHIEVEMENT OF STEROID-FREE REMISSION IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE DURING TREATMENT WITH RISANKIZUMAB
    Schreiber, Stefan
    Cross, Raymond K.
    Panaccione, Remo
    D'Haens, Geert
    Bossuyt, Peter
    Colombel, Jean Frederic
    Louis, Edouard
    Dubinsky, Marla
    Kligys, Kristina
    Neimark, Ezequiel
    Song, Alexandra P.
    Zambrano, Javier A.
    Cheng, Erica
    Ferrante, Marc
    GASTROENTEROLOGY, 2022, 162 (07) : S966 - S966
  • [24] Endoscopic endpoints in biologic clinical trials and beyond: the case for Crohn's Disease
    Adriaanse, Marlou P. M.
    Lowenberg, Mark
    D'Haens, Geert R. A. M.
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2024, 24 (12) : 1353 - 1362
  • [25] Studies show rapid clinical and endoscopic Response with Upadacitinib and Risankizumab in Crohn's Disease
    不详
    VISCERAL MEDICINE, 2024, 40 (03)
  • [26] Adalimumab sustains steroid-free remission after 3 years of therapy for Crohn's disease
    Kamm, M. A.
    Hanauer, S. B.
    Panaccione, R.
    Colombel, J. -F.
    Sandborn, W. J.
    Pollack, P. F.
    Zhou, Q.
    Robinson, A. M.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2011, 34 (03) : 306 - 317
  • [27] UPADACITINIB EXPOSURE-RESPONSE RELATIONSHIPS FOR EFFICACY IN SUBJECTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE - ANALYSIS OF CELEST STUDY
    Mohamed, Mohamed-Eslam F.
    Kluender, Ben
    Lacerda, Ana P.
    Othman, Ahmed A.
    GASTROENTEROLOGY, 2018, 154 (06) : S386 - S386
  • [28] New Phase II Data on Upadacitinib with clinical and endoscopic Findings at Week 52 in Crohn's Disease is announced by AbbVie
    不详
    VISCERAL MEDICINE, 2018, 34 (02) : 160 - 160
  • [29] Upadacitinib improves symptomatic responses in patients with moderately to severely active Crohn's disease
    Blumenstein, I.
    Torres, J.
    Ma, C.
    Lindsay, J. O.
    Ungaro, R.
    Thin, L.
    Lacerda, A. P.
    Anyanwu, S. I.
    Garrison, A.
    Ford, S.
    Louis, E.
    JOURNAL OF CROHNS & COLITIS, 2024, 18 : II000 - I1001
  • [30] Upadacitinib Achieves Clinical and Endoscopic Outcomes in Crohn's Disease Regardless of Prior Biologic Exposure
    Peyrin-Biroulet, Laurent
    Panaccione, Remo
    Louis, Edouard
    Atreya, Raja
    Rubin, David T.
    Lindsay, James O.
    Siffledeen, Jesse
    Lukin, Dana J.
    Wright, John
    Watanabe, Kenji
    Ford, Sharanya
    Remple, Valencia P.
    Lacerda, Ana P.
    Dubcenco, Elena
    Garrison, Andrew
    Zhou, Qian
    Berg, Sofie
    Anyanwu, Samuel I.
    Schreiber, Stefan
    CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2024, 22 (10) : 2096 - 2106
12345